Sunday 18 October 2026
Export SABS’s income statement to Excel — free account
SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.
2.53
0.06
−2.32%
Follow SABS
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 0 | 3 | 1 | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | 3.06 | (1.78) | (1.43) | (5.52) | — |
P/S ratio |
— | 0.00 | 3.51 | 1.18 | 17.26 | 21.57 | — |
Altman Z″-Score (non-manufacturers) |
— | 6.80 | 0.59 | (4.32) | (0.53) | (11.84) | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | (4.63) | (2.05) | — | — | — |
P/Operating CF |
— | (150,140.83) | (43.77) | (18.19) | (2.87) | (3.68) | — |
P/B ratio |
— | 93,838.02 | 5.54 | 0.91 | 0.67 | 1.35 | — |
Price to Tangible BV |
— | 93,838.02 | 5.54 | 0.91 | 0.67 | 1.35 | — |
EV/Sales |
— | 0.00 | 2.92 | 0.73 | (6.47) | 10.83 | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.42 | 0.00 | — |
EV/Operating CF |
— | 0.00 | 89.45 | (0.74) | 0.58 | (0.51) | — |
EV/FCF |
— | 0.00 | (19.84) | (0.68) | 0.57 | (0.51) | — |
Quick Ratio |
— | 3.00 | 1.80 | 1.37 | 5.23 | 2.61 | 9.13 |
Current Ratio |
— | 3.11 | 1.90 | 1.47 | 5.45 | 2.98 | 9.46 |
Net Debt/EBITDA |
— | (0.40) | 3.05 | 0.42 | 1.55 | 0.46 | 2.03 |
Debt/Assets |
0.00% | 7.24% | 4.64% | 8.19% | 4.07% | 7.41% | 1.81% |
Debt/Equity |
— | 0.11 | 0.10 | 0.13 | 0.06 | 0.13 | 0.02 |
Asset Turnover |
— | 1.95 | 0.88 | 0.36 | 0.03 | 0.02 | 0.00 |
Operating CF/Net income |
— | 0.50 | (0.12) | 1.25 | 0.60 | 1.01 | (10.51) |
Capex/Depreciation |
— | (23.21) | (6.62) | (0.63) | (0.04) | (0.07) | (0.31) |
Interest Coverage |
— | 43.81 | (45.48) | (95.88) | (120.76) | (134.77) | (203.38) |
| — | 51.88% | (44.21%) | (53.85%) | (95.51%) | (81.92%) | 4.80% | |
| — | 71.17% | (24.91%) | (28.39%) | (62.58%) | (53.23%) | 3.93% | |
ROIC |
— | 42.13% | (302.49%) | (89.55%) | (573.17%) | (316.08%) | (52.73%) |
Return on Tangible Assets |
— | 52.61% | (35.68%) | (61.74%) | (62.21%) | (109.38%) | 4.11% |
Average Days of Receivables |
— | 135.92 | 48.03 | 84.85 | 0.00 | 15.18 | 0.00 |
Research and Development Expense of Revenue |
— | 50.52% | 93.93% | 152.44% | 737.61% | 2,287.64% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 12.26% | 28.07% | 68.54% | 1,062.94% | 1,057.27% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 2.35% | 3.80% | 11.19% | 108.25% | 222.46% | 0.00% |
Graham Net Nets |
— | 0.00 | 0.04 | 0.08 | 0.83 | 0.16 | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | 0.00% | (8.03%) | (65.84%) | (110.63%) | (97.10%) | — |
Free Cash Flow Yield |
— | 0.00% | (4.19%) | (90.31%) | (65.39%) | (98.65%) | — |
Revenue per Share |
— | 21.75 | 22.27 | 5.49 | 0.41 | 0.14 | 0.00 |
Operating CF per Share |
— | 3.94 | 0.73 | (5.39) | (4.55) | (3.70) | (2.32) |
Capex per Share |
— | (5.01) | (4.00) | (0.48) | (0.03) | (0.04) | (0.05) |
Free Cash Flow per Share |
— | (1.07) | (3.28) | (5.87) | (4.58) | (3.74) | (2.37) |
Cash per Share |
— | 4.97 | 14.46 | 3.46 | 10.24 | 2.24 | 5.00 |
Shareholders Equity per Share |
— | 15.36 | 14.10 | 7.14 | 10.38 | 2.80 | 7.84 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 15.36 | 14.10 | 7.14 | 10.38 | 2.80 | 7.84 |
Free Cash Flow |
— | (2.72) | (8.96) | (25.55) | (25.27) | (34.63) | (45.71) |
Working Capital |
— | 23.39 | 23.74 | 7.10 | 48.09 | 15.81 | 90.37 |
Capital Expenditures |
— | (12.72) | (10.94) | (2.09) | (0.15) | (0.34) | (0.93) |
Net Current Asset Value |
— | 16.92 | 7.60 | 2.25 | 32.27 | 5.57 | 79.74 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.38 | 0.00 | — |
Capex to Sales |
— | 0.23 | 0.18 | 0.09 | 0.07 | 0.26 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.04 | 0.07 | 0.14 | 0.19 | 0.30 | 0.22 |
Cash ROIC |
— | (4.88%) | (10.94%) | (50.82%) | (21.55%) | (69.25%) | (18.20%) |
Accounts Receivable Turnover |
— | 3.87 | 4.26 | 3.52 | 0.00 | 0.47 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 14.29 | 14.29 | 6.78 | — | 2.81 | 0.50 |
Average Payables |
— | 5.92 | 5.92 | 4.07 | 2.31 | 1.32 | 2.42 |
Average Assets |
— | 28.27 | 68.84 | 66.02 | 67.42 | 64.07 | 108.50 |
Average Common Equity |
— | 38.78 | 38.78 | 34.80 | 44.18 | 41.63 | 88.73 |
Columns are period end dates